High-Dose Albumin Therapy for Neuroprotection in Acute Ischemic Stroke
PI: Myron Ginsberg, MD - University of Miami
Status: Enrolling, current NIH funding for the ALIAS Phase III Trial extends to May 2010

The purpose of the ALIAS trial is to evaluate the effectiveness of high-dose, intravenous human serum albumin.  Human serum albumin is a natural protein already in clinical use for a variety of indications.  In animal laboratory studies it has been shown that it reduces the size of the infarction (amount of tissue death) in the brain and improves neurological function after a stroke and also decreases or eliminates the brain swelling that may occur; these effects may reduce or prevent the brain damage resulting from a stroke in humans.